Indications
Therapeutic Asset Ratings
9,922 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
nxp800
Ovarian Clear Cell Tumor
Nuvectis Pharma, Inc.
P1
CC
(43)
nxp900
Lung Adenocarcinoma
Nuvectis Pharma, Inc.
P1
CC
(43)
nxp900
Non-Small Cell Squamous Lung Carcinoma
Nuvectis Pharma, Inc.
P1
CC
(43)
Ny-Eso-1 Tcr Redirected Autologous T Cell Product
Metastatic Melanoma
Centre Hospitalier Universitaire Vaudois
P1
CC
(43)
Oatd-02
Ovarian Carcinoma
Molecure S.A.
P1
CC
(43)
Oatd-02
Exocrine Pancreatic Carcinoma
Molecure S.A.
P1
CC
(43)
oba01
Non-Small Cell Lung Carcinoma
Lu Shun
P1
CC
(43)
Obecabtagene Autoleucel Chimeric Antigen Receptor
Chronic Progressive Multiple Sclerosis
Autolus Limited
P1
CC
(43)
Obinutuzumab
Cervical Squamous Cell Carcinoma
NeoTX Therapeutics Ltd.
P1
CC
(43)
Obinutuzumab
Estrogen-Receptor Positive Breast Cancer
NeoTX Therapeutics Ltd.
P1
CC
(43)
Obinutuzumab
Small Cell Lung Carcinoma
Chugai Pharmaceutical
P1
CC
(43)
Obinutuzumab
Neoplasm Of Mature B-Cells
BeOne Medicines
P1
CC
(43)
Obinutuzumab
Diffuse Large B-Cell Lymphoma Of The Central Nervous System
National Cancer Institute (NCI)
P1
CC
(43)
Obx-115
Neoplasm
M.D. Anderson Cancer Center
P1
CC
(43)
Ocrelizumab
CNS Demyelinating Autoimmune Disease
Indapta Therapeutics, INC.
P1
CC
(43)
Ocrelizumab
Immune System Disorder
Indapta Therapeutics, INC.
P1
CC
(43)
Ocrelizumab
Nervous System Disorder
Indapta Therapeutics, INC.
P1
CC
(43)
Oct-598
Gastroesophageal Cancer
Oscotec Inc.
P1
CC
(43)
okn4395
Dedifferentiated Liposarcoma
Epkin
P1
CC
(43)
okn4395
Gastric Adenocarcinoma
Epkin
P1
CC
(43)
okn4395
Gastroesophageal Adenocarcinoma
Epkin
P1
CC
(43)
okn4395
Leiomyosarcoma
Epkin
P1
CC
(43)
okn4395
Myxofibrosarcoma
Epkin
P1
CC
(43)
okn4395
Solitary Fibrous Tumor
Epkin
P1
CC
(43)
okn4395
Undifferentiated Pleomorphic Sarcoma
Epkin
P1
CC
(43)
Showing 3001 to 3025 of 9,922 assets
Previous
Page 121 of 397
Next
